Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials
Restricted accessResearch articleFirst published online August, 2013
Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials
Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line pharmacological treatment for depression and are the most commonly prescribed class of antidepressants. However, there is substantial evidence that noradrenaline has a role in the pathogenesis and treatment of depression. This review aims to examine the evidence of including noradrenaline reuptake inhibition with serotonin reuptake inhibition with respect to increasing efficacy in the treatment of depression. Evidence from meta-analysis of randomised controlled trials (RCTs) and randomised pragmatic trials was found in support of greater efficacy of the serotonin noradrenaline reuptake inhibitors (SNRIs), venlafaxine and duloxetine, in moderate to severe depression compared to SSRIs but no evidence was found for superiority of milnacipran. There is sufficient current evidence that demonstrates an increase in efficacy, when noradrenaline reuptake is added to serotonin (5-HT) reuptake, to suggest that patients with severe depression or those who have failed to reach remission with a SSRI may benefit from treatment with a SNRI. However, as these conclusions are drawn from the evidence derived from meta-analyses and pragmatic trials, large adequately powered RCTs using optimal dosing regimens and clinically relevant outcome measures in severe depression and SSRI treatment failures are still required to confirm these findings.
AllardPGramLTimdahlK. (2004) Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry19: 1123–1130.
2.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association.
3.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders Fourth Edition., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
4.
BaldomeroEBUbagoJGCercosCL. (2005) Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety22: 68–76.
5.
BallesterosJCalladoLFGutierrezM (2007) An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol27: 219–221.
6.
BauerMTharmanathanPVolzHP. (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci259: 172–185.
7.
BielskiRJVenturaDChangCC (2004) A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry65: 1190–1196.
8.
BlierPSaint-AndreEHebertC. (2007) Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol10: 41–50.
9.
ChenFLarsenMBSanchezC. (2005) The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol15: 193–198.
10.
ChenXHuangXHuY (2012) Efficacy and safety of Duloxetine versus paroxetine for adults’ depression: A meta-analysis. Chinese Journal of Evidence-Based Medicine12: 320–325.
11.
ChenZMZhangJHLiZW. (2001) Venlafaxine versus imipramine,sertraline in treating depression. . Chinese Journal of New Drugs and Clinical Remedies20: 109–111.
12.
CiprianiABrambillaPFurukawaT. (2005) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev: CD004185.
13.
CiprianiAFurukawaTASalantiG. (2009a) Comparative efficacy and acceptability of 12 newgeneration antidepressants: A multiple-treatments meta-analysis. Lancet373: 746–758.
14.
CiprianiAKoestersMFurukawaTA. (2012a) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev10: CD006533.
15.
CiprianiALa FerlaTFurukawaTA. (2010) Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev: D006117.
16.
CiprianiAPurgatoMFurukawaTA. (2012b) Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 7: CD006534.
17.
CiprianiASantilliCFurukawaTA. (2009b) Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev: 2; CD006532.
18.
CookRJSackettDL (1995) The number needed to treat: A clinically useful measure of treatment effect. Brit Med J310: 452–454.
19.
Danish University Antidepressant Group (DUAG) (1986) Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl)90: 131–138.
20.
Danish University Antidepressant Group (DUAG) (1990) Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord18: 289–299.
21.
De SilvaVAHanwellaR (2012) Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies. Int Clin Psychopharmacol27: 8–16.
22.
DebonnelGSaint-AndreEHebertC. (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol10: 51–61.
23.
DeecherDCBeyerCEJohnstonG. (2006) Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther318: 657–665.
EckertLLanconC (2006) Duloxetine compared with fluoxetine and venlafaxine: Use of meta-regression analysis for indirect comparisons. BMC Psychiatry6: 30.
26.
EinarsonTRAddisAMittmannN. (1998) Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. Can J Clin Pharmacol5: 205–216.
27.
EinarsonTRArikianSRCascianoJ. (1999) Comparison of extended-release venlafaxine, serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin Ther21: 296–308.
28.
EntsuahARHuangHThaseME (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry62: 869–877.
29.
GartlehnerGGaynesBNHansenRA. (2008a) Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med149: 734–750.
30.
GartlehnerGHansenRAMorganLC. (2011) Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med155: 772–785.
31.
GartlehnerGThiedaPHansenRA. (2008b) Comparative risk for harms of second-generation antidepressants : A systematic review and meta-analysis. Drug Saf31: 851–865.
32.
GartlehnerGThalerKHansenRA. (2009) The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf32: 1159–1173.
33.
GirardiPPompiliMInnamoratiM. (2009) Duloxetine in acute major depression: Review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol24: 177–190.
34.
HansenRAGartlehnerGLohrKN. (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med143: 415–426.
35.
HigginsJPTGreenS (eds) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available at: www.cochrane-handbook.org.
36.
IsacssonGAdlerM (2012) Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression. Acta Psychiatr Scand125: 453–459.
37.
KasperSSpadoneCVerpillatP. (2006) Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis. Int Clin Psychopharmacol21: 105–110.
38.
KatzmanMATriccoACMcIntoshD. (2007) Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry68: 1845–1859.
39.
KennedySHAndersenHFLamRW (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci31: 122–131.
40.
KennedySHAndersenHFThaseME (2009) Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin25: 161–175.
41.
KhanABoseAAlexopoulosGS. (2007) Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig27: 481–492.
42.
KhanAKhanSRWalensG. (2003) Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology28: 552–557.
43.
KhanALeventhalRMKhanSR. (2002) Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol22: 40–45.
44.
KobakKATaylorLHDottlSL. (1997) A computer-administered telephone interview to identify mental disorders. JAMA278: 905–910.
45.
KoestersMZhangYMaYC. (2011) What can we learn from Chinese randomized controlled trials? A systematic review and meta-analysis of Chinese venlafaxine studies. J Clin Psychopharmacol31: 194–200.
46.
KornsteinSGLiDMaoY. (2009) Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectr14: 326–333.
47.
LamRWAndersenHFWadeAG (2008) Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials. Int Clin Psychopharmacol23: 181–187.
48.
LamRWLonnSLDespiegelN (2010) Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis. Int Clin Psychopharmacol25: 199–203.
49.
LaneP (2008) Handling drop-out in longitudinal clinical trials: A comparison of the LOCF and MMRM approaches. Pharm Stat7: 93–106.
50.
LecrubierY (1995) Clinical utility of venlafaxine in comparison with other antidepressants. Int Clin Psychopharmacol10: S29–S35.
51.
Lenox-SmithAMacdonaldMBradleyA. (2011) Duloxetine vs individual generic selective serotonin reuptake inhibitors (SSRIs) in the treatment of a severe depressive episode. J Psychopharmacol25: A19.
52.
Lenox-SmithAJJiangQ (2008) Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol23: 113–119.
53.
LiebermanJAGreenhouseJHamerRM. (2005) Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology30: 445–460.
54.
MachadoMEinarsonTR (2010) Comparison of SSRIs and SNRIs in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther35: 177–188.
55.
MachadoMIskedjianMRuizI. (2006) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials. Curr Med Res Opin22: 1825–1837.
56.
MallinckrodtCHClarkWSDavidSR (2001) Accounting for dropout bias using mixed-effects models. J Biopharm Stat11: 9–21.
57.
MallinckrodtCHPrakashAHoustonJP. (2007) Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology56: 73–85.
58.
MartinezJMKatonWGreistJH. (2012) A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol27: 17–26.
59.
MehtonenOPSogaardJRoponenP. (2000) Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry61: 95–100.
60.
MontgomerySAHuusomAKBothmerJ (2004) A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology50: 57–64.
61.
NakagawaAWatanabeNOmoriIM. (2009) Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev: CD006529.
62.
National Institute for Health and Clinical Excellence (2010) The Treatment and Management of Depression in Adults. National Clinical Guideline 90, London: National Institue for Health and Clinical Excellence.
63.
NemeroffCBEntsuahRBenattiaI. (2008) Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry63: 424–434.
64.
OmoriIMWatanabeNNakagawaA. (2009) Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: Meta-analysis. J Psychopharmacol23: 539–550.
65.
OmoriIMWatanabeNNakagawaA. (2010) Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev: CD006114.
66.
OslinDWTen HaveTRStreimJE. (2003) Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry64: 875–882.
67.
PapakostasGIFavaM (2007) A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol17: 32–36.
68.
PapakostasGIFavaMThaseME (2008) Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches. Biol Psychiatry63: 699–704.
69.
PapakostasGIThaseMEFavaM. (2007) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry62: 1217–1227.
PuechAMontgomerySAProstJF. (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol12:99–108.
72.
PuozzoCPanconiEDeprezD (2002) Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol17: S25–S35.
73.
RamsbergJAsseburgCHenrikssonM (2012) Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One7: e42003.
74.
RichelsonE (2003) Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry64: S5–S12.
75.
RushAJTrivediMHWisniewskiSR. (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med354: 1231–1242.
76.
SchachtADyachkovaYWaltonRJ (2013) Critical evaluation of mixed treatment comparison meta-analyses using examples assessing antidepressants and opioid detoxification treatments. Int J Methods Psychiatr Res22: 166–174.
77.
SchmittABBauerMVolzHP. (2009) Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci259: 329–339.
78.
SchuelerYBKoestersMWieselerB. (2011) A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand123: 247–265.
79.
SheltonCEntsuahRPadmanabhanSK. (2005) Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol20: 233–238.
80.
SiddiquiOHungHMO’NeillR (2009) MMRM vs LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat19: 227–246.
81.
SinyorMLevittAJCheungAH. (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry71: 270–279.
82.
SmithDDempsterCGlanvilleJ. (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry180: 396–404.
83.
StahlSMEntsuahRRudolphRL (2002) Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry52: 1166–1174.
84.
StahlSMGradyMMMoretC. (2005) SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr10: 732–747.
85.
TakanoAHalldinCFardeL (2013) SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study. Psychopharmacology (Berl)226: 147–153.
86.
ThaseMEEntsuahARRudolphRL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry178: 234–241.
87.
ThaseMENinanPTMusgnungJJ. (2011) Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: A randomized, open-label study. Prim Care Companion CNS Disord13(1):e1-e9.
88.
ThaseMEPritchettYLOssannaMJ. (2007) Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol27: 672–676.
89.
TrivediMHRushAJWisniewskiSR. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry163: 28–40.
90.
WadeAGembertKFloreaI (2007) A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin23: 1605–1614.
91.
WeinmannSBeckerTKoestersM (2008) Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl)196: 511-520; discussion 521–512.
